virus
play
signific
role
seriou
infect
adult
sometim
lead
need
hospit
admiss
intens
care
unit
especi
case
sever
respiratori
distress
encephalopathi
influenza
parainfluenza
virus
syncyti
respiratori
viru
herp
virus
adenovirur
frequent
caus
sever
infect
review
literatur
perform
order
updat
epidemiolog
pathogenesi
therapeut
approach
viral
infect
affect
immunocompet
patient
furthermor
ventilatorassoci
pneumonia
vap
frequent
nosocomi
infect
intens
care
unit
high
morbid
mortal
rate
mainli
bacteri
diseas
although
potenti
role
virus
pathogen
copathogen
vap
discuss
therefor
brief
review
potenti
pathogen
role
virus
vap
also
perform
resumen
lo
viru
tienen
un
papel
important
dentro
de
la
infeccion
grave
en
lo
pacient
adulto
que
en
alguna
ocasion
llegan
necesitar
e
ingreso
en
unidad
de
cuidado
intensivo
especialment
en
caso
de
de
respiratorio
del
adulto
encef
la
infeccion
por
viru
influenza
parainfluenza
viru
sinciti
respiratorio
herp
viru
adenoviru
son
la
que
frecuentement
causan
esto
cuadro
se
ha
realizado
una
de
la
literatura
pormenorizada
actualizada
de
manifestacion
de
la
infeccion
viral
en
pacient
inmunocompetent
por
otro
lado
si
bien
la
asociada
tien
como
palabra
clave
infeccion
viral
inmunocompetent
sdra
unidad
de
cuidado
intensivo
septic
process
remain
one
main
caus
morbiditymort
icu
throughout
world
context
viral
infect
caus
mani
communityacquir
infect
gener
popul
also
great
relev
critic
patient
particularli
seriou
respiratori
viral
infect
among
caus
seriou
communityacquir
pneumonia
requir
hospit
admiss
virus
account
case
underli
etiolog
known
virus
invad
airway
group
follow
provid
main
acut
viral
entiti
caus
common
seriou
respiratori
disord
immunocompet
adult
encompass
term
febril
respiratori
ill
fri
causal
virus
tabl
group
two
main
categori
myxovirus
includ
differ
type
associ
influenza
b
c
adenovirus
involv
differ
type
isol
human
anoth
parallel
categori
correspond
parainfluenza
virus
number
type
known
descript
given
pneumon
condit
caus
hsv
vzv
ebv
cmv
describ
review
correspond
immun
defici
patient
season
flu
viru
influenza
viru
sever
acut
respiratori
syndrom
sar
caus
recent
manifest
rna
viru
coronaviru
coronavirida
first
describ
epidem
outbreak
diseas
exhibit
biphas
clinic
cours
prodrom
manifest
fever
chill
muscl
pain
nausea
headach
progress
within
day
respiratori
alter
sever
hypoxemia
case
respiratori
failur
ard
diagnosi
establish
pcr
immunofluoresc
though
viral
cultur
elisa
also
use
treatment
fundament
support
case
corticosteroid
prove
use
follow
develop
ard
report
mortal
rate
greater
patient
year
age
transmiss
via
droplet
aerial
rout
contact
clinic
pictur
character
prodrom
manifest
fever
chill
muscl
pain
abdomin
pain
rapid
progress
toward
respiratori
failur
ard
coagulopathi
shock
diagnosi
base
serolog
test
treatment
compris
support
measur
administr
ribavirin
hfr
effect
hcp
transmiss
contact
urin
excrement
infect
mice
hemorrhag
fever
condit
diseas
associ
hemorrhag
exanthema
caus
arbovirus
belong
famili
alphavirida
flavivirida
special
mention
group
virus
caus
yellow
fever
biphas
condit
character
onset
fever
remiss
reappear
system
bleed
liver
failur
gastrointestin
disord
exanthema
endem
equatori
africa
equatori
america
area
caribbean
asia
dengu
import
insect
transmit
diseas
human
acut
manifest
involv
fever
headach
nausea
vomit
maculopapular
exanthema
muscl
pain
joint
pain
ebola
marburg
virus
recent
advanc
virolog
diagnosi
result
substanti
improv
viral
cultur
yield
rapid
shellvial
assay
increas
sensit
specif
viral
antigen
detect
techniqu
expans
avail
serolog
techniqu
particularli
advanc
method
base
nucleic
acid
amplif
procedur
polymeras
chain
reaction
pcr
wide
use
diagnost
techniqu
main
clinic
condit
report
tabl
current
avail
antivir
agent
tabl
belong
two
group
accord
mechan
action
one
hand
amantadin
rimantadin
act
upon
protein
influenza
viru
inhibit
capac
lower
endosom
ph
essenti
order
destroy
viral
envelop
releas
nucleocapsid
amantadin
effect
influenza
viru
influenza
b
viru
latter
lack
protein
instead
substitut
protein
call
nb
affect
amantadin
hand
oseltamivir
tamiflu
zanamivir
relenza
block
activ
site
neuraminidas
thu
prevent
spread
viru
drug
demonstr
activ
influenza
b
virus
among
support
measur
common
treatment
mani
diseas
tabl
mention
must
made
appropri
oxygen
therapi
corticosteroid
aerosol
therapi
bronchodil
corticosteroid
ribavirin
nonpharmacolog
manag
critic
patient
seriou
febril
respiratori
ill
vari
accord
implic
infecti
agent
suspect
confirm
sever
respiratori
condit
though
case
present
clinic
similar
allow
us
establish
certain
manag
pattern
thu
case
intens
support
measur
necessari
fluid
amin
renal
replac
therapi
use
septic
shock
origin
patient
usual
suffer
seriou
lung
injuri
thu
lead
need
mechan
ventil
case
ard
develop
protect
strategi
must
appli
mechan
ventil
low
tidal
volum
ml
kg
high
peep
valu
reduc
atelectas
area
milder
case
sometim
respond
favor
earli
noninvas
ventil
niv
though
controversi
use
techniqu
patient
although
etiolog
ventilatorassoci
pneumonia
vap
alway
classifi
bacteri
fact
present
episod
record
etiolog
h
n
ot
e
n
de
fin
e
pa
rt
icu
la
rli
follow
introduct
highli
sensit
techniqu
detect
virus
respiratori
tract
studi
publish
last
decad
point
possibl
role
virus
pathogenesi
import
infect
especi
preval
icu
although
date
regular
diagnost
standard
establish
none
public
establish
causal
relationship
isol
infecti
episod
moreov
evid
studi
clinic
trial
role
antivir
agent
purportedli
viral
process
french
prospect
studi
conduct
univers
hospit
includ
patient
ventil
hour
period
month
n
tracheal
aspir
studi
detect
presenc
virus
use
differ
techniqu
includ
pcr
isol
virus
rhinoviru
herp
simpl
influenza
respiratori
syncyti
enteroviru
parainfluenza
adenoviru
coronaviru
cmv
detect
patient
case
attribut
viral
pneumonia
identifi
vap
episod
though
must
mention
herp
simplex
viru
type
hsvi
isol
vap
episod
therefor
hsvi
appear
like
implic
viral
agent
also
suggest
recent
nation
seri
sever
intern
studi
publish
last
decad
report
frequenc
vari
median
although
reactiv
cmv
diseas
classic
link
patient
cellular
immun
alter
last
decad
reactiv
also
report
immunocompet
critic
patient
incid
variabl
depend
diagnost
method
use
cultur
pcr
rang
recent
studi
ventil
patient
suspect
vap
yield
posit
serolog
test
acanthomaeba
polyphaga
though
episod
show
posit
bal
bacteri
cultur
mimiviru
previous
associ
episod
communityacquir
nosocomi
pneumonia
reactiv
latent
viru
appear
initi
mechan
patient
hsvicaus
pneumonia
icu
exist
prior
posit
serolog
test
preced
presenc
mucocutan
lesion
posit
pharyng
smear
episod
confirm
point
reactiv
caus
instrument
trauma
airway
occur
oropharyng
mucosa
upper
respiratori
tract
posterior
microaspir
toward
distal
zone
directli
bronchial
mucosa
reactiv
start
third
fifth
day
mechan
ventil
reach
peak
viral
load
exponenti
expans
day
copiesml
follow
slow
declin
viral
load
correl
diagnosi
viral
bronchopneumon
frequent
risk
factor
hsvi
infect
lower
respiratori
tract
presenc
mucocutan
herpet
lesion
posit
pharyng
smear
tracheal
mucos
lesion
thrombocytopenia
high
sofa
andor
apach
ii
score
mechan
ventil
day
old
age
use
corticosteroid
admiss
icu
hsvi
igg
posit
upon
admiss
mention
reactiv
cmv
frequent
critic
patient
occur
day
stay
icu
reactiv
may
begin
lung
parenchyma
activ
sepsi
demonstr
anim
model
involv
latent
cmv
infect
caus
persist
increas
cytokinemedi
inflammatori
respons
risk
factor
describ
activ
cmv
infect
immunocompet
patient
subject
mechan
ventil
blood
transfus
previou
hospit
age
prior
corticosteroid
use
clinic
studi
publish
mimiviru
vap
risk
factor
associ
posit
serolog
test
viru
durat
mechan
ventil
prior
bronchoalveolar
lavag
detect
virus
absenc
enter
nutrit
role
hsv
caus
lower
respiratori
tract
infect
remain
defin
isol
viru
may
correspond
contamin
upper
respiratori
tract
mucos
viral
excret
bronchopneumon
sinc
half
case
purport
viral
vap
show
coexist
bacteri
isol
accordingli
isol
may
simpli
sever
marker
may
reflect
exist
pathogen
right
number
studi
attempt
document
true
incid
vap
caus
cmv
total
patient
diagnos
ard
suspect
vap
neg
cultur
result
histopatholog
find
compat
cmv
pneumonia
studi
publish
eleven
year
later
author
base
vivo
biopsi
popul
patient
demonstr
high
incid
cmv
pneumonia
low
diagnost
yield
pcr
bal
sampl
cultur
sensit
specif
recent
studi
incid
activ
cmv
diseas
found
high
seri
immunocompet
patient
subject
ventil
hour
view
cmv
suspect
caus
vap
presenc
persist
infiltr
lack
clinic
improv
neg
bacteri
cultur
use
pcr
evalu
possibl
cmv
reactiv
antivir
therapi
start
necessari
confirm
diagnosi
may
establish
lung
biopsi
patient
infect
hsv
requir
longer
mechan
ventil
hospit
stay
though
studi
abl
demonstr
increas
mortal
data
adequ
studi
avail
allow
recommend
antivir
treatment
case
hsv
infect
though
clinic
trial
clearli
need
given
grow
incid
infect
associ
longer
stay
mechan
ventil
sinc
patient
benefit
could
deriv
result
previous
cite
studi
evalu
incid
risk
factor
prognosi
patient
activ
cmv
diseas
latter
seen
associ
longer
stay
day
mechan
ventil
increas
number
nosocomi
infect
compar
patient
without
activ
cmv
diseas
mortal
icu
versu
p
hospit
versu
p
higher
cmv
diseas
group
import
tendenc
toward
statist
signific
multivari
analysi
activ
diseas
found
independ
associ
mortal
icu
along
apach
ii
score
tabl
summar
main
characterist
vap
